| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTAG2 |
| Uniprot No | O75638 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-210aa |
| 氨基酸序列 | MQAEGQGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGAARASGPRGGAPRGPHGGAASAQDGRCPCGARRPDSRLLQLHITMPFSSPMEAELVRRILSRDAAPLPRPGAVLKDFTVSGNLLFMSVRDQDREGAGRMRVVGWGLGSASPEGQKARDLRTPKHKVSEQRPGTPGPPPPEGAQGDGCRGVAFNVMFSAPHI |
| 预测分子量 | 28.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CTAG2重组蛋白的3篇文献摘要概述：
1. **文献名称**: "Recombinant CTAG2 protein as a potential biomarker for lung cancer diagnosis"
**作者**: Zhang Y, et al.
**摘要**: 该研究通过大肠杆菌表达系统成功制备了重组CTAG2蛋白，并验证其在非小细胞肺癌患者血清中的特异性表达。结果显示，重组CTAG2在肺癌诊断中具有高敏感性和特异性，提示其作为肿瘤标志物的潜力。
2. **文献名称**: "Expression and purification of CTAG2 for T-cell receptor-based immunotherapy"
**作者**: Smith JL, et al.
**摘要**: 研究者利用杆状病毒-昆虫细胞系统表达可溶性CTAG2重组蛋白，通过亲和层析纯化后，证实其能够有效激活抗原特异性T细胞，为基于CTAG2的肿瘤免疫治疗(如CAR-T/TCR-T)提供功能性抗原工具。
3. **文献名称**: "Structural characterization of CTAG2 and its interaction with HLA class I molecules"
**作者**: García-Barreno P, et al.
**摘要**: 该研究通过X射线晶体学解析了重组CTAG2蛋白的三维结构，并发现其与HLA-A*02:01分子的强结合能力。此结果为设计靶向CTAG2的肽疫苗及免疫检测方法提供了分子基础。
*注：上述文献为示例，实际引用需根据具体研究检索PubMed/Google Scholar等数据库，并核对原文内容。*
CTAG2 (Cancer-Testis Antigen Family Member 2), also known as NY-ESO-1. is a member of the cancer-testis antigen (CTA) family, which comprises proteins typically expressed in germline cells but aberrantly reactivated in various cancers. Discovered through serological analysis of recombinant cDNA expression libraries (SEREX), CTAG2 is encoded by the *CTAG2* gene located on the X chromosome. Its restricted expression in normal tissues (primarily testis and placenta) and frequent re-expression in malignancies make it a promising target for cancer immunotherapy.
In cancer biology, CTAG2 is classified as a tumor-associated antigen due to its immunogenic properties. It is expressed in a wide range of cancers, including melanoma, lung, ovarian, and bladder carcinomas, as well as sarcoma and myeloma. This selective expression pattern arises from epigenetic modifications, particularly demethylation of promoter regions in tumor cells. The protein contains multiple HLA class I and II epitopes, enabling recognition by cytotoxic T cells and antibody-producing B cells.
Recombinant CTAG2 protein is produced via genetic engineering systems (e.g., *E. coli* or mammalian cell cultures) for research and clinical applications. Its primary utility lies in developing diagnostic tools, monitoring treatment responses, and designing antigen-specific immunotherapies. Notably, CTAG2-directed therapies, including peptide vaccines, adoptive T-cell transfer, and engineered T-cell receptors, have shown clinical potential. The antigen's strong immunogenicity is evidenced by spontaneous antibody and T-cell responses in 40-50% of patients with CTAG2-positive tumors, correlating with improved clinical outcomes in some cases. Current challenges involve enhancing antigen presentation efficiency and overcoming tumor immune evasion mechanisms in therapeutic applications.
×
